Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin

The pathogenesis of central nervous system disease during human immunodeficiency virus type 1 (HIV-1) infection revolves around productive viral infection of brain macrophages and microglia. Neuronal losses in the cortex and subcortical gray matter accompany macrophage infection. The question of how viral infection of brain macrophages ultimately leads to central nervous system (CNS) pathology remains unanswered. Our previous work demonstrated high-level production of tumor necrosis factor alpha, interleukin 1 beta, arachidonic acid metabolites, and platelet-activating factor (PAF) from HIV-infected monocytes and astroglia (H. E. Gendelman, P. Genis, M. Jett, and H. S. L. M. Nottet, in E. Major, ed., Technical Advances in AIDS Research in the Nervous System, in press; P. Genis, M. Jett, E. W. Bernton, H. A. Gelbard, K. Dzenko, R. Keane, L. Resnick, D. J. Volsky, L. G. Epstein, and H. E. Gendelman, J. Exp. Med. 176:1703-1718, 1992). These factors, together, were neurotoxic. The relative role(s) of each of these candidate neurotoxins in HIV-1-related CNS dysfunction was not unraveled by these initial experiments. We now report that PAF is produced during HIV-1-infected monocyte-astroglia interactions. PAF was detected at high levels in CSF of HIV-1-infected patients with immunosuppression and signs of CNS dysfunction. The biologic significance of the results for neurological disease was determined by addition of PAF to cultures of primary human fetal cortical or rat postnatal retinal ganglion neurons. Here, PAF at concentrations of > or = 300 pg/ml produced neuronal death. The N-methyl-D-aspartate receptor antagonist MK-801 or memantine partially blocked the neurotoxic effects of PAF. The identification of PAF as an HIV-1-induced neurotoxin provides new insights into how HIV-1 causes neurological impairment and how it may ultimately be ameliorated.

[1]  P. Lantos,et al.  Neuronal loss in the frontal cortex in HIV infection , 1991, The Lancet.

[2]  H. Gendelman,et al.  Experimental Model Systems for Studies of HIV Encephalitis , 1995 .

[3]  P. J. Clarke,et al.  The immunolocalisation of the neuroendocrine specific protein PGP9.5 during neurogenesis in the rat. , 1991, Brain research. Developmental brain research.

[4]  M. V. Hogan,et al.  Long-term potentiation in the hippocampus induced by platelet-activating factor , 1993, Neuron.

[5]  D. Tauck,et al.  Voltage‐dependent conductances of solitary ganglion cells dissociated from the rat retina. , 1987, The Journal of physiology.

[6]  J. Glass,et al.  Cytokine expression in the brain during the acquired immunodeficiency syndrome , 1992, Annals of neurology.

[7]  M. Criscuoli,et al.  Catecholamines released from the adrenal medulla exert a compensatory, protective effect at β2‐adrenoceptors against Paf‐induced death in mice , 1988, British journal of pharmacology.

[8]  T. Hökfelt,et al.  Leukotrienes in the rat central nervous system. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Lipton,et al.  HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. , 1990, Science.

[10]  M. Louder,et al.  Overexpression of nef as a marker for restricted HIV‐1 infection of astrocytes in postmortem pediatric central nervous tissues , 1994, Neurology.

[11]  E. Masliah,et al.  Neocortical damage during HIV infection , 1991, Annals of neurology.

[12]  L. Montagnier,et al.  Human immunodeficiency virus type 1–infected monocytic cells can destroy human neural cells after cell‐to‐cell adhesion , 1992, Annals of neurology.

[13]  Andrew J. Saykin,et al.  Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection , 1991, Neurology.

[14]  H. Gendelman,et al.  Neurological Aspects of Human Immunodeficiency Virus Infection , 1992 .

[15]  J. Ward,et al.  Neuropsychological functioning in human immunodeficiency virus type 1 seropositive children infected through neonatal blood transfusion. , 1991, Pediatrics.

[16]  Takao Shimizu,et al.  Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung , 1991, Nature.

[17]  L. Prockop.  AIDS dementia complex. , 1988, The Journal of legal medicine.

[18]  W. Maxwell Cowan,et al.  Rat hippocampal neurons in dispersed cell culture , 1977, Brain Research.

[19]  D. Lefer,et al.  Role of platelet-activating factor-acether in mediating guinea pig anaphylaxis. , 1986, Science.

[20]  Stefan Fischer,et al.  Platelet-neutrophil interactions. (12S)-hydroxyeicosatetraen-1,20-dioic acid: a new eicosanoid synthesized by unstimulated neutrophils from (12S)-20-dihydroxyeicosatetraenoic acid. , 1988, The Journal of biological chemistry.

[21]  A. Shahar.  A Dissection and tissue culture manual of the nervous system , 1989 .

[22]  M. McGrath,et al.  Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. , 1991, The Journal of clinical investigation.

[23]  S. Shukla.  Platelet‐activating factor receptor and signal transduction mechanisms 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  D. Gingras,et al.  Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes. , 1991, Immunology.

[25]  S. Hwang.  Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. , 1990, Journal of lipid mediators.

[26]  S. Lipton,et al.  Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity , 1991, Neuron.

[27]  S. Lipton.  Human immunodeficiency virus-infected macrophages, gp120, and N-methyl-D-aspartate receptor-mediated neurotoxicity. , 1993, Annals of Neurology.

[28]  A. Volterra,et al.  High Sensitivity of Glutamate Uptake to Extracellular Free Arachidonic Acid Levels in Rat Cortical Synaptosomes and Astrocytes , 1992, Journal of neurochemistry.

[29]  C. Zorumski,et al.  Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor , 1992, Neuron.

[30]  H. Gendelman,et al.  No direct neuronotoxicity by HIV-1 virions or culture fluids from HIV-1-infected T cells or monocytes. , 1992, AIDS research and human retroviruses.

[31]  W. Freeman,et al.  Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. , 1992, American journal of ophthalmology.

[32]  C. Wiley,et al.  Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Navia,et al.  The AIDS dementia complex: I. Clinical features , 1986, Annals of neurology.

[34]  L. Nowak,et al.  Magnesium gates glutamate-activated channels in mouse central neurones , 1984, Nature.

[35]  E. Cho,et al.  Pathologic features of AIDS encephalopathy in children: evidence for LAV/HTLV-III infection of brain. , 1986, Human pathology.

[36]  R. Masland,et al.  Monoclonal antibody to Thy-1 enhances regeneration of processes by rat retinal ganglion cells in culture. , 1984, Science.

[37]  A. Ogura,et al.  Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons , 1992, Neuron.

[38]  D. Giulian,et al.  Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1 , 1990, Science.

[39]  S. Snyder,et al.  Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Epstein,et al.  Human immunodeficiency virus type 1 (HIV-1) infection of the nervous system: a review. , 1988, Immunodeficiency reviews.

[41]  A. Harel-Bellan,et al.  Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Sharer,et al.  Pathology of HIV‐1 Infection of the Central Nervous System. A review , 1992, Journal of neuropathology and experimental neurology.

[43]  H. Gendelman,et al.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Gendelman,et al.  Human immunodeficiency virus type 1 infection of the nervous system: Pathogenetic mechanisms , 1993, Annals of neurology.

[45]  D. Attwell,et al.  Potentiation of NMDA receptor currents by arachidonic acid , 1992, Nature.